Nomination Committee proposal for the Board for the 2012 Annual General Meeting

Nomination Committee proposal for the Board for the 2012 Annual General Meeting

Huddinge – Medivir AB (OMX: MVIR), the research-based specialty pharmaceutical
company focused on infectious diseases, has today announced the Nomination
Committee’s proposals for a new Board of Directors for the 2012 Annual General
Meeting.

The Nomination Committee consists of representatives of the three largest
shareholders who agreed to participate on the Committee at the end of the third
quarter of 2011, as well as the Chairman of the Board. The composition of the
Nomination Committee 2011-2012 has been as follows:

  · Anders Algotsson, chairman and representative for AFA Försäkring
  · Caroline af Ugglas, representative for Skandia Liv
  · Bo Öberg, representative for Class A shareholders
  · Göran Pettersson, chairman of the board, Medivir

The Nomination Committee proposes that the 2012 AGM select a new board by
reelecting the Board's current four members, Göran Pettersson, Björn C.
Andersson, Anna Malm Bernsten and Ingemar Kihlström, as well as election of two
new members, Anders Hallberg and Rolf A. Classon. The proposal also includes
reelection of Göran Pettersson, chairman of the board.

Anders Hallberg (b. 1945) has been Professor of Medicinal Chemistry at the
Faculty of Pharmacy, Uppsala University, since 1990. From 1990 to 2006 he also
had various assignments as a scientific advisor for AstraZeneca and smaller
pharmaceutical companies. Before that he was head of the Medicinal Chemistry
department at Astra in Lund. From 2006 to 2011 he was rector magnificus at
Uppsala University. Anders Hallberg is currently a member of the Swedish
government's research advisory committee, the Royal Academy of Sciences and the
Royal Academy of Engineering Sciences.

Rolf A. Classon (b. 1945) holds a Master’s degree in Political Science from the
University of Gothenburg. He has extensive experience from senior positions in
the pharmaceutical and medical technology industries, including Pharmacia and
Bayer Diagnostics, and as global CEO of Bayer HealthCare. He has also been a
divisional general manager at Swedish Match. Rolf’s current assignments include
board assignments at Hill-Rom Corporation (USA), Auxilium Pharmaceuticals (USA),
Tecan Group (Switzerland), Fresenius Medical Care (Germany) and Aerocrine AB
(Sweden).

A full presentation of the Nomination Committee's proposal will be available in
the upcoming notice of the AGM 2012.
 

For more information about Medivir, please contact:
Medivir                                              Mobil: +46 708 537 292 
Rein Piir, EVP Corporate Affairs & IR

About Medivir
Medivir is an emerging research-based specialty pharmaceutical company focused
on the development of high-value treatments for infectious diseases. Medivir has
world class expertise in the inhibition of polymerases and protease enzymes, as
well as drug development in this field, which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is TMC435, a
protease inhibitor in phase III clinical development for treatment of hepatitis
C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia
to ensure timely commercialisation of TMC435 in the Nordic markets, once
approved.

Medivir’s first product, the unique cold sore product Xerese®/Xerclear®, was
launched on the US market in February 2011. Xerese®/Xerclear®, which has been
approved in both the US and Europe, is being launched in collaboration with
GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North
America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has
retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company’s website:
www.medivir.com